BMJ4h
Alzheimer’s disease: What treatments could be rolled out in the next few years?
NICE has said it expects to evaluate dozens of potential treatments for Alzheimer’s disease over the next few years. Elisabeth Mahase examines what we know about these drugs This year the National ...
News Medical on MSN2d
Sleep apnea raises dementia risk in older women
Researchers determine the differential risk of dementia among men and women based on the presence of obstructive sleep apnea.
ALZFORUM13d
Lecanemab Bested Three Other Antibodies at Binding Soluble Aβ Aggregates
Lecanemab Favors Early Aggregates. Fluorescently labeled lecanemab (green) bound most strongly to soluble Aβ aggregates ...
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study
On Tuesday, Coya Therapeutics, Inc. (NASDAQ:COYA) released results from the placebo-controlled Phase 2 trial of LD IL-2 in ...
Rolling Out13d
Caffeine consumption and its impact on Alzheimer’s disease risk
A groundbreaking research conducted in France has unveiled compelling evidence linking caffeine consumption to reduced ...
Health.com on MSN14d
Study Finds Link Between Higher Caffeine Consumption and Lower Risk of Memory Loss
A new study found that increased caffeine consumption may influence your risk of Alzheimer's or other forms of dementia. But experts still have questions on the association between caffeine and memory ...
New Multi-Marker Blood Test from Lucent Diagnostics Increases the Number of Patients Receiving Early Alzheimer’s Disease Diagnostic Information
Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), has introduced LucentAD Complete, a new multi-marker ...
Promising Phase II Trial Results Support Buy Rating for Coya Therapeutics’ Alzheimer’s Treatment
Chardan Capital analyst Keay Nakae reiterated a Buy rating on Coya Therapeutics, Inc. (COYA – Research Report) today and set a price ...
Lecanemab Data Presented At CTAD On Early Initiation And Long-Term Treatment Suggest Increased Patient Benefit With Maintained Safety Profile
Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...